XP21510

XP21510 is a patented new chemical entity discovered by XenoPort. It is a Transported Prodrug of tranexamic acid. Tranexamic acid is a man-made derivative of the naturally occurring amino acid known as lysine. It is approved in many countries in Europe and Asia for the treatment of women with menorrhagia, or heavy menstrual bleeding.

We have licensed rights to develop and commercialize XP21510 in the United States to Xanodyne Pharmaceuticals, Inc. At this time, XP21510 is in preclinical development.